AIT Therapeutics Reports Third Quarter 2017 Financial Results

NEW YORK, AITB,(GLOBE NEWSWIRE)  AIT Therapeutics, Inc. (OTC:AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced financial results for the three- and nine-months ended September 30, 2017. Operational Highlights include: On October 23, 2017, the last patient completed treatment in our Phase 2 NO-NTM abscessus trial for the treatment of Nontuberculous Mycobacteria (NTM) abscessus lung disease.  The Company expects to
http://bit.ly/2zMFsTi